The recent advent of nanomedicine holds potential to revolutionize cancer therapy. This innovative discipline has paved the way for the emergence of a new class of drugs based on nanoengineered particles. These "nanodrugs" are designed to greatly enhance drug therapeutic indices. First-generation nanodrugs consisted of conventional anti-cancer drugs loaded into/onto nanoengineered particles (nanocarriers) devoid of targeting features (non-targeted nanodrugs). Non-targeted nanodrugs have provided the opportunity to carry large amounts of drugs, including poorly watersoluble and/or permeable drugs, to several types of tumors, improving the therapeutic index with respect to comparable free drugs. Although effective, the primary delivery mechanism of nontargeted nanodrugs was through passive tissue accumulation, due to pathophysiological differences between tumor-associated and healthy vessels, and through non-specific targeting of cell subsets, posing the danger of off-target binding and effects. Recently, the therapeutic indices of certain anti-cancer drugs were further improved by attaching targeting ligands to nanodrugs (targetednanodrugs). Targeted-nanodrugs selectively bind to cognate receptors expressed on target cells and enter cells more efficiently than non-targeted formulations. Although these advancements have been sufficiently beneficial to place targeted-nanodrugs into clinical development for use in cancer therapy, they also come at a price. The addition of ligands to drug-loaded nanocarriers often leads to additional synthesis steps and costs, and more complex biological performance relative to ligand-devoid nanodrugs. Here, we will discuss the benefits and challenges facing the addition of targeting features to nanodrugs for cancer therapy. Copyright © 2014 American Scientific Publishers All rights reserved.

Bottini, M., Sacchetti, C., Pietroiusti, A., Bellucci, S., Magrini, A., Rosato, N., et al. (2014). Targeted nanodrugs for cancer therapy: Prospects and challenges. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 14(1), 98-114 [10.1166/jnn.2014.9010].

Targeted nanodrugs for cancer therapy: Prospects and challenges

PIETROIUSTI, ANTONIO;MAGRINI, ANDREA;ROSATO, NICOLA;BOTTINI, NUNZIO
2014-01-01

Abstract

The recent advent of nanomedicine holds potential to revolutionize cancer therapy. This innovative discipline has paved the way for the emergence of a new class of drugs based on nanoengineered particles. These "nanodrugs" are designed to greatly enhance drug therapeutic indices. First-generation nanodrugs consisted of conventional anti-cancer drugs loaded into/onto nanoengineered particles (nanocarriers) devoid of targeting features (non-targeted nanodrugs). Non-targeted nanodrugs have provided the opportunity to carry large amounts of drugs, including poorly watersoluble and/or permeable drugs, to several types of tumors, improving the therapeutic index with respect to comparable free drugs. Although effective, the primary delivery mechanism of nontargeted nanodrugs was through passive tissue accumulation, due to pathophysiological differences between tumor-associated and healthy vessels, and through non-specific targeting of cell subsets, posing the danger of off-target binding and effects. Recently, the therapeutic indices of certain anti-cancer drugs were further improved by attaching targeting ligands to nanodrugs (targetednanodrugs). Targeted-nanodrugs selectively bind to cognate receptors expressed on target cells and enter cells more efficiently than non-targeted formulations. Although these advancements have been sufficiently beneficial to place targeted-nanodrugs into clinical development for use in cancer therapy, they also come at a price. The addition of ligands to drug-loaded nanocarriers often leads to additional synthesis steps and costs, and more complex biological performance relative to ligand-devoid nanodrugs. Here, we will discuss the benefits and challenges facing the addition of targeting features to nanodrugs for cancer therapy. Copyright © 2014 American Scientific Publishers All rights reserved.
2014
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/44 - MEDICINA DEL LAVORO
English
Cancer therapy; Ligands; Nanodrugs; Targeting; Therapeutic index; Tumor microenvironment; Condensed Matter Physics; Chemistry (all); Materials Science (all); Bioengineering; Biomedical Engineering
Bottini, M., Sacchetti, C., Pietroiusti, A., Bellucci, S., Magrini, A., Rosato, N., et al. (2014). Targeted nanodrugs for cancer therapy: Prospects and challenges. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 14(1), 98-114 [10.1166/jnn.2014.9010].
Bottini, M; Sacchetti, C; Pietroiusti, A; Bellucci, S; Magrini, A; Rosato, N; Bottini, N
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
J Nanosci Nanotechnol 2014 VQR Rosato 3.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 696.53 kB
Formato Adobe PDF
696.53 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/121299
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
social impact